ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Growth Hormone
Phase 3

Tesofensine

Tesofensine

Also known as: NS2330, Tesomet

Overview

Key Facts

Primary Goal: A triple monoamine reuptake inhibitor originally developed for neurodegenerative diseases that was repurposed for obesity after significant weight loss was observed in clinical trials

A triple monoamine reuptake inhibitor originally developed for neurodegenerative diseases that was repurposed for obesity after significant weight loss was observed in clinical trials. Tesofensine suppresses appetite and increases thermogenesis through enhanced norepinephrine, dopamine, and serotonin signaling. Half-Life ~200-300 hours Typical Dose 0.25–1 mg Frequency Once daily (oral) Cycle Length 12-24 weeks under medical supervision

Dosing Information

Half-Life

~200-300 hours

Typical Dose

0.25–1 mg

Frequency

Once daily (oral)

Cycle Length

12-24 weeks under medical supervision

Administration Routes:

oral

Storage & Reconstitution

Unreconstituted (Powder)

Temperature15–25°C (59–77°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature15–25°C (59–77°F)
Duration2-4 weeks

Research Summary

Phase 3

Phase 2 trials demonstrated that tesofensine 0.5 mg produced approximately 12.8% body weight loss over 24 weeks, roughly double that of existing anti-obesity medications at the time. Phase 3 trials (TESORA) are ongoing in several countries. The compound also showed improvements in metabolic parameters including HbA1c and lipid profiles. Cardiovascular safety monitoring remains a key focus.

Frequently Asked Questions

Common questions about Tesofensine

UK-Specific Information

Exclusive data points and guidance for UK residents using Tesofensine

UK Lab Testing

US Lab Testing

Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With